Leading Mass Tort Attorney Joseph Fantini Reveals Secret Behind Zantac Cancer Compensation Program's Litigation Process

Top Mass Tort Attorney Joseph Fantini discloses that scores of attorneys pitching for potential Zantac lawsuit legal claims often funnel all their caseload through to the Zantac Cancer Compensation Program. For more information please visit https://www.zantacsupport.org

It was revealed today that scores of attorneys pitching for potential Zantac lawsuit legal claims often funnel all their caseload through to the Zantac Cancer Compensation Program, its founder has disclosed.

For more information please visit https://www.zantacsupport.org/

Joseph Fantini, of Zantac Cancer Compensation Program (ZCCP) said the general public was largely unaware that the compensation program he founded was the main focal point of many Zantac legal claims.

During an episode of The 5 Minute Legal Insights Podcast, Fantini said: “A little secret I want to let everyone in on is that those lawyers advertising their services to handle potential Zantc lawsuits are often turning the cases over to us.”

He explained, “It’s because we have the expertise in handling these cases. The main problem is that when other law firms are marketing for these cases they don’t have staff trained specifically in Zantac litigation and have experience in the pharmaceutical legal framework.

“The main difference is that when a client calls the ZCCP, they speak to a dedicated case manager who has been working on this type of Zantac litigation for years, and will be with them throughout the case.“

The client will also be assigned an experienced and highly-trained paralegal that knows Zantac. “When you are looking for a law firm, it’s very important to make sure you get one that specializes in these cases,” he emphasized.

There are currently over 75,000 individuals in Zantac legal claims, and Fantini fully expects the final figure to more than double.

The U.S. Food and Drug Administration (FDA) took the unusual step in April 2020 in recalling ranitidine, the generic version of Zantac, over concerns of a potentially high dosage content of N-Nitrosodimethylamine (NDMA), a known carcinogen, in the drug.

Tests revealed Zantac could have 3,000 times more NDMA content than the FDA’s recommended daily dose. NDMA can cause several cancers affecting the prostate, bladder, breast, colon, esophageal, gastric, kidney, liver, pancreatic, and stomach.

Fantini added that once signed up for the product liability cases, his team will be honed to establish two grounds: the proof of usage of medication, and the diagnosis and treatment for cancer.

“We have a dedicated team of medical coordinators who know how to get the information as quickly as possible. It can be very challenging to source the information required, but our trained staff have processed thousands of requests,” he emphasized.

“For example, a lot of pharmacies have their own authorizations that need to have information filled out to their liking before they release records to us. We deal with this all the time and don’t face the obstacles that other legal firms do.”

The Zantac Cancer Compensation Program also works with experts in their field to evaluate all the medical information coming in.
“That’s another major difference between our compensation program and other law firms. We know what to do, identify the experts required and get their findings immediately. This is one of the cornerstones of the ZCCP and helps us expedite the process and get a quick result for the client,” Fantini said.

Source: http://RecommendedExperts.biz

Contact Info:
Name: Joseph Fantini
Email: Send Email
Organization: Rosen Injury Lawyers - Zantac
Address: 101 Greenwood Ave, Jenkintown, PA 19046,
Phone: (215) 310-9961
Website: https://www.zantacsupport.org/

Source URL: http://RecommendedExperts.biz

Release ID: 89020184